Novo and DJ Khaled have teamed up to share how the DJ, rapper and record producer has incorporated the GLP-1 drug Wegovy into his weight-loss routine.
Khaled frequently posts on social media about his “walking golf” routine that enables him to hit his daily step goal while playing the game he loves. This week, Khaled shared his new routine: walking, golf and Wegovy. The star began taking Wegovy after noticing—and having a friend notice—that extra weight he was carrying was affecting his performance.
“When I turned 50 last year, I started a new chapter of more goals, more wins and more blessings. And managing my weight is part of it—so, no more gatekeeping,” Khaled said in a statement. “I partnered with Wegovy to bring people fully behind the scenes into my day-to-day routine and let them know they've got options.”
Khaled kicked off the Novo partnership with a pair of social media posts. In the first post, the DJ tells viewers he has seen social media comments about his weight loss. Khaled attributes the weight loss to “walking golf,” hitting his 10,000-step goal and Wegovy.
The DJ filmed the second video while walking during a round of golf, telling viewers that “the weight is coming off” and mentioning Wegovy six times in about 40 seconds. Having started using the GLP-1 drug in October 2025, Khaled has now lost 75 pounds, or about 25% of his body weight. On average, patients lost 15% of their weight while using 2.4-mg Wegovy injections in a 68-week trial.
Khaled’s videos are part of a campaign in which he will share his experience of weight loss, fatherhood, his diet and exercise routine and the moment he knew it was time to talk to his doctor about treatment.
Novo is rolling out the campaign months after partnering with DJ Khaled on its 2026 Super Bowl TV spot. That ad, which focused on Novo’s oral Wegovy product, was a hit. TV outcomes company EDO named the commercial the 10th most effective Super Bowl ad across all industries. The ad generated 3.7 times more engagement than the median Super Bowl commercial.
The marketing activities are part of Novo's efforts to re-energize its obesity franchise following a period in which Eli Lilly and drug compounders slowed its growth. Novo has “shifted messaging around the marketing of Wegovy products, to focus on weight loss in addition to real-world health benefits,” BMO Capital Markets analysts said in a Nov. 11 note to investors.